Biodesix: Fast Revenue Growth, Strong Margins — A Long Trade Below Diagnostics Multiples

Hook & thesis

Biodesix is a diagnostics company that has shown durable top-line momentum and enviable unit economics in recent quarters. Q2 2026 revenue came in at $26.9 million, up 34% year-over-year, and management reiterated full-year 2026 revenue guidance of $108-114 million (roughly +25% growth). At the same time the company reported an 82% gross margin in Q2 — a sign that revenue growth is translating into valuable, scalable product economics.

Despite those fundamentals, the stock currently trades around $27.21 with a market capitalization near $287 million and an enterprise value of roughly $302.5 million. That places Biodesix at about 2.8x price-to-sales and ~2.94x EV/sales, metrics that are modest for a diagnostics firm growing revenue in the mid-to-high double digits. For an active trader willing to accept execution and commercialization risk, there is a defined asymmetric trade: capture upside as the market re-rates the company while limiting downside with a disciplined stop.

What the business does and why it matters

Biodesix operates blood-based diagnostic tests focused on lung disease and oncology. Its suite includes Nodify CDT, Nodify XL2, GeneStrat (ddPCR and NGS), and VeriStrat. The core fundamental driver is test volume growth combined with reimbursement expansion and high gross margins that scale with volume. In Q4 2025 the company reported $28.8 million in revenue (a 41% increase) and full-year 2025 revenue of $88.5 million (+24%), showing a pattern of accelerating commercial traction. Continued uptake of lung diagnostics and firm reimbursement dynamics would sustain revenue growth and move operating leverage through the high gross margin profile.

Concrete numbers to anchor the story

Valuation framing

On a headline basis, Biodesix trades at ~2.8x price-to-sales and ~2.94x EV/sales. For a diagnostics company growing revenue >20% with high (82%) gross margins, those multiples are modest compared with many established diagnostics peers that typically trade at higher sales multiples because of predictable earnings and scale. The stock's price-to-book sits very elevated (around 30x) because the company is still loss-making on an EPS basis (negative EPS and negative free cash flow). That combination - strong sales growth and very good gross margins but negative bottom-line cash flow - is the crux: the market is placing a discount for execution and profitability risk, but not necessarily for growth potential.

Trade idea (actionable)

Thesis: Buy on continued revenue progress and investor recognition. The market has room to re-rate higher if management hits guidance, shows sustainable reimbursement expansion, and demonstrates a path to positive adjusted EBITDA consistency.

• Entry: $27.00
• Stop loss: $23.50
• Target: $36.00
• Time horizon: long term (180 trading days) - this is a tactical position intended to capture a re-rating over several quarters as revenue growth, margin expansion, and potential positive operating leverage materialize.

Why these levels? Entry close to current trading keeps slippage low. The stop at $23.50 limits downside to roughly 13% from the entry and sits below recent moving averages and shorter-term technical support (10-day and 20-day SMAs are in the mid-$20s). The target of $36.00 is roughly 30% above entry and implies a re-rating toward higher sales multiples (it would price ahead of the 52-week high and reflect a pick-up in investor confidence). Given the company’s revenue growth profile and 82% gross margin, a successful execution story could justify that multiple expansion within 6-9 months.

Catalysts to watch

• Investor conferences and management outreach - leadership participation in events (announced for September) can accelerate analyst coverage and institutional interest.
• Quarterly results and guidance - hitting or exceeding the FY 2026 guidance ($108-114M) will be a direct re-rating catalyst.
• Reimbursement expansion and clinical adoption - continued expansion of reimbursement for lung diagnostics and positive clinical utility data will directly increase volume.
• Progress toward adjusted EBITDA positivity - management has previously pointed to positive adjusted EBITDA timing; clear evidence of this trend would materially derisk the story.

Risks and counterarguments

Below are the principal risks that could invalidate the trade thesis, followed by a short counterargument to my own bullish view.

• Profitability and cash burn: Trailing free cash flow is negative (-$20.24M). The company may need to access capital markets if operating cash flows do not improve quickly, which would dilute shareholders and pressure the stock.
• Execution risk on commercialization: High gross margins are encouraging, but test volume growth needs to continue to support the revenue guidance. If volumes slow or reimbursement setbacks occur, revenue and margin projections would suffer.
• Regulatory / reimbursement setbacks: Diagnostic reimbursement is volatile by nature. Any adverse decision or delay in payer coverage could materially impact revenue growth.
• Valuation multiple compression: Even with growth, the stock's forward re-rating is not guaranteed. If market sentiment in the diagnostics sector cools, multiples could compress further, keeping the stock rangebound or lower.
• Short interest and volatility: Short interest has been non-trivial at times (several hundred thousand shares reported in recent settlements and elevated short volume on some sessions), which can amplify directional moves and intraday volatility.

Counterargument: A reasonable bear case is that Biodesix cannot convert high-margin revenue growth into consistent positive operating cash flow. If growth slows while the company continues to burn cash, the market will de-rate the business and the multiple could compress below current levels. That outcome would pressure the stock well below the proposed stop.

What would change my mind

I would turn more cautious if any of the following occur: (1) management cuts FY guidance or signals slower-than-expected reimbursement uptake; (2) free cash flow trends do not show clear improvement over the next two quarters; (3) clinical data or external payer decisions materially weaken the addressable market for the company’s lung diagnostics. Conversely, I would become more bullish if Biodesix prints consecutive quarters of better-than-guidance revenue growth, demonstrates sustainable adjusted EBITDA improvement, or secures materially expanded payer coverage.

Position sizing and execution notes

This is a medium-risk trade that sits between pure growth-biotech speculation and large-cap diagnostics steadiness. For core traders, limit initial exposure to a percentage of portfolio size that reflects the stock’s volatility and cash burn profile. Use the stop at $23.50 to cut losses quickly, and consider trimming into strength on the way toward the $36.00 target to lock in gains.

Bottom line

Biodesix combines credible revenue growth and very healthy gross margins with an attractive sales multiple relative to expectations for a high-growth diagnostics company. The primary risks are execution-oriented: cash flow and reimbursement are the story’s pivot points. For disciplined traders who accept that binary risk, a long position entered near $27.00 with a $23.50 stop and $36.00 target over a 180 trading day horizon provides a clear, risk-defined way to participate in a potential re-rating.

Key dates & references

• Q2 2026 revenue announcement discussed in the company's investor materials on 09/03/2026.
• Management participation in investor conferences in September 2026 (useful for new coverage and liquidity events).